Det er 6 år gamle nyheter som de nå skal koke suppe på.
Ultimovacs believes can attractively
complement the cancer vaccine under development by Ultimovacs. The TET-platform™ addresses the
general challenge of so called “adjuvants” that enhance the desired response of the immune system
to a vaccine. It makes it possible to incorporate adjuvant and the vaccine itself into one molecule.
When using the technology from Immuneed, the antibodies formed by a previous vaccine can
function as adjuvant for a new vaccine. This principle is general and can be applied as an adjuvant for
many different vaccines. The principle and the technology have been successfully validated in
different pre-clinical models.
Ultimovacs considers the TET-platform™ technology as a promising and general strategy to
strengthen and increase T cell responses against cancer vaccine peptides. In parallel with the
continued development of the therapeutic cancer vaccine UV1, Ultimovacs will therefore pursue the
development of a new first-in-class cancer vaccine solution based on the proprietary TET-platform™
technology.
Kanskje det funker på lakselus?